Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Research & Development: 2012-2024

Historic Research & Development for China Pharma Holdings (CPHI) over the last 13 years, with Dec 2024 value amounting to $283,942.

  • China Pharma Holdings' Research & Development fell 53.98% to $40,321 in Q3 2025 from the same period last year, while for Sep 2025 it was $91,407, marking a year-over-year decrease of 78.79%. This contributed to the annual value of $283,942 for FY2024, which is 18.27% up from last year.
  • China Pharma Holdings' Research & Development amounted to $283,942 in FY2024, which was up 18.27% from $240,080 recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Research & Development ranged from a high of $377,964 in FY2020 and a low of $185,858 during FY2022.
  • In the last 3 years, China Pharma Holdings' Research & Development had a median value of $240,080 in 2023 and averaged $236,627.
  • In the last 5 years, China Pharma Holdings' Research & Development skyrocketed by 64.59% in 2020 and then plummeted by 41.73% in 2022.
  • China Pharma Holdings' Research & Development (Yearly) stood at $377,964 in 2020, then dropped by 15.61% to $318,964 in 2021, then slumped by 41.73% to $185,858 in 2022, then increased by 29.17% to $240,080 in 2023, then grew by 18.27% to $283,942 in 2024.